Acquired hemophilia type A in the intensive care unit. Case reports
DOI:
https://doi.org/10.24875/RMIMSS.M20000039Keywords:
Hemophilia A, Critical Illness, Hemorrhage, Immunosuppressive AgentsAbstract
Background: Acquired hemophilia type A (AHA) is a rare and deadly condition. It is caused by autoantibodies to factor VIII. It is a diagnostic and therapeutic challenge with the potential development of complications, which can put at risk the life of the person presenting it.
Case reports: We present two cases of patients that have bleeding and bleeding disorders, with the diagnosis of AHA diagnosed by activated partial thromboplastin time prolonged in isolated form, late correction with plasma, presence of factor VIII inhibitor of coagulation and decreased activity of factor VIII. The first case had a neoplasm and the second was in the puerperium, as risk factors. The severity of the condition and the risk of complications and/or death make it necessary to receive care in an intensive care unit.
Conclusions: AHA is a rare clinical condition with high mortality. In patients in critical condition with persistent hemorrhage and alterations in the coagulation tests, it should be considered as part of the differential diagnosis. The management of this entity is multidisciplinary, and hemostatic and immunosuppressive treatments must be provided early.
Downloads
References
Hunt B. Bleeding and coagulopathies in critical care. N Engl J Med. 2014;370(9):847-59.
Gulati D, Novak A, Stanworth S. Common haemostasis issues in major bleeding and critical illness. Clin Med (Lond). 2018;18(4):320-3.
Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10(4):222.
Wheeler A, Rice T. Coagulopathy in critically ill patients:part 2-soluble clotting factors and hemostatic testing. Chest. 2010;137(1):185-94.
Hurwitz A, Massone R, Lopez BR. Acquired bleeding disorders. Hematol Oncol Clin North Am. 2017;31(6):1123-45.
Batty P, Palmer B, Chalmers E, Liesner R, Rangarajan S, Talks K, et al. A national survey of immunosuppression strategies for acquired haemophilia A. Haemophilia. 2015;21(1):e73-6.
Tagariello G, Sartori R, Radossi P, Risato R, Roveroni G, Tassinari C, et al. Acquired haemophilia A as a blood transfusion emergency. Blood Transfus. 2008;6(1):8-11.
Tufano A, Coppola A, Guida A, Cimino E, De Gregorio A, Cerbone A, et al. Acquired haemophilia A in the elderly:case reports. Curr Geront Ger Res. 2010;2010:927503. doi:10.1155/2010/927503
Baudo F, Caimi T, Cataldo F. Diagnosis and treatment of acquired haemophilia. Haemophilia. 2010;16(102):102-6. doi:10.1111/j.1365-2516.2010.02232
Sborov D, Rodgers G. How I manage patients with acquired haemophilia A. Br J Haemat. 2013;161(2):157-65. doi:10.1111/bjh.12228
García-Chávez J, Vela-Ojeda J, García Manzano A, Majluf-Cruz A. Respuesta a largo plazo con rituximab en una paciente con hemofilia adquirida. Rev Invest Clin. 2011;63(2):210-2.
Martínez-Murillo C, Quintana-González S, Ambriz-Fernández R, Domínguez-García V, Rodríguez-Moyado H, Arias-Jaloma J, et al. Informe de dos casos con enfermedad de von Willebrand adquirida y uno con hemofilia A adquirida. Rev Invest Clin. 1995;47(3):211-6.
Chai-Adisaksopha C, Rattarittamrog E, Norasetthada L, Tantiworawit A, Nawarawong W. Younger age at presentation of acquired haemophilia A in Asian countries:a single centre study and systematic review. Haemophilia. 2014;20(3):e205-10.
Bong J, Guillet B, Cam-Duchez V, Goudemand J, Levesque H. Outcome of acquired haemophilia in France:the prospective SACHA (Surveillance des Auto Anticorps au Cours de l'Hémophilie Acquise) registry. Haemophilia. 2013;19(4):564-70.
Collins PW. Management of acquired haemophilia A. J Thromb Haemost. 2011;9(Suppl 1):226-35.
Croom KF, McCormark PL. Recombinant factor VIIa (eptacog alfa). A review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. Biodrugs. 2008;22(2):121-36.
Franchini M, Lippi G. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review. Thromb Haemost. 2010;104(5):931-40.
Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor:the FEIBA NovoSeven comparative (FENOC) study. Blood. 2007;109(2):546-51.
Ehrlich H, Henzl M, Gomperts E. Safety of factor VIII inhibitor bypass activity (FEIBA):10-year complication of thrombotic adverse events. Haemophilia. 2002;8(2):83-90.
Huth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Hematologica. 2009;94(4):566-75.
Xu Y, Zhang X, Zhao Y, Zhao L, Qiu H, Wu D. Successful treatment of a patient with acquired haemophilia A with a combination of a low dose rituximab and recombinant human FVIIa. Haemophilia. 2013;19(2):e84-102.
Ingerslev J, Hvitfeldt L, Sosrensen B. Factor VIIa:use in patients with hemophilia. TATM. 2002;5(5 Suppl):15-9.
Zeitler H, Ulrich-Merzenich G, Panek D, Goldmann G, Vidovic N, Hermann H, et al. Extracorporeal treatment for acute and long term outcome patients with life threatening acquired hemophilia. Transfus Med Hemother. 2012;39(4):264-70.
Collins P, Hirsch S, Baglin T, Dolan G, Hanley J, Makris M, et al. Acquired hemophilia A in the United Kingdom:A 2 years national surveillance study by the United Kingdom Haemophilia Centre Doctors'Organisation. Blood. 2007;109(5):1870-7.
Chai-Adisaksopha C, Hillis C, Thabane L, Lorio A. A systematic review of definitions and reporting of bleeding outcome measures in haemophilia. Haemophilia. 2015;21(6):731-5.
Zeitler H, Merzenich G, Goldmann G, Vidovic N, Brackmann H, Oldenburg J. The relevance of the bleeding severity in the treatment of acquired haemophilia –an update of a single centre experience with 67 patients. Haemophilia. 2010;16(102):95-101.
Downloads
Published
Issue
Section
License
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.
